DKF-MA102 — Competitive Intelligence Brief

DKF-MA102 (DKF-MA102) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

phase 3 molecular target Cardiovascular Small molecule

Target snapshot

DKF-MA102 (DKF-MA102) — Dongkook Pharmaceutical Co., Ltd.. DKF-MA102 is a small molecule drug that targets the molecular target.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DKF-MA102 TARGET	DKF-MA102	Dongkook Pharmaceutical Co., Ltd.	phase 3		molecular target
PF-07104091 monotherapy dose expansion (ovarian)	pf-07104091-monotherapy-dose-expansion-ovarian	Pfizer	marketed	small molecule	[insert molecular target]
Entecavir+Fuzheng Huayu+TCM Granule	Entecavir+Fuzheng Huayu+TCM Granule	ShuGuang Hospital	marketed	Nucleoside reverse transcriptase inhibitor + Traditional Chinese Medicine herbal combination	HBV reverse transcriptase (entecavir component); multiple herbal constituents with unclear specific molecular targets
ECx1	ECx1	Oregon Health and Science University	marketed	small molecule	ECx1's molecular target is unknown
PF-06882961 (Cohorts 1 and 2)	pf-06882961-cohorts-1-and-2	Pfizer	marketed	pharmacological class	molecular target
Allr3	allr3	Pfizer	marketed	The pharmacological class of ALLR3 is not specified.	The molecular target of ALLR3 is not specified.
D-Col Personal Hygiene Convenience Kit	col	Pfizer	marketed	not well-documented	various molecular targets

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.